Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.
| Added by | amaraver |
|---|---|
| Group name | EquipeAM |
| Item Type | Attachment |
| Title | PubMed entry |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/34746886 |
| Accessed | 2022/08/31 - 16:19:43 |
| Date Added | 2022/08/31 - 14:19:43 |
| Date Modified | 2022/08/31 - 14:19:43 |
| Parent item | Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study |
Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).
U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)
Institut de Recherche en Cancérologie de